Financials

Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2008 Financial Results

Published in Medical Letter on the CDC and FDA, February 24th, 2008

Aeolus Pharmaceuticals, Inc. (OTCBB:AOLS) announced financial results for the three months ended December 31, 2007. The Company reported a net loss of $641,000, or $0.02 per share, compared to a loss of $949,000, or $0.03 per share, for the three months ended December 31, 2006, a decrease of 32%.

"The Company remains focused on research and development with studies underway to test AEOL 10150 as a protective agent against mustard gas exposure, to confirm AEOL 11207's potential as a treatment for Parkinson's disease, and to determine attractive candidates from our pipeline to address colitis and chronic obstructive pulmonary disease ("COPD"). We expect that these studies...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2008-02-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry